Interleukin-6 regulation of prostate cancer cell growth

Journal of Cellular Biochemistry

Volumn 95, Issue 3, 2005, Pages 497-505

  Culig, Zoran ^a   Steiner, Hannes ^a   Bartsch, Georg ^a   Hobisch, Alfred ^b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b General Hospital Feldkirch   (Austria)

Author keywords

Androgen receptor; Interleukin 6; JAK STAT; MAPK; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; INTERLEUKIN 6; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; ONCOSTATIN M; PHOSPHATIDYLINOSITOL 3 KINASE; STAT PROTEIN;

AUTOCRINE EFFECT; CANCER GROWTH; CARCINOGENESIS; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; HUMAN; HUMAN CELL; IMMUNOREGULATION; LIGAND BINDING; MALE; NEUROENDOCRINE SYSTEM; PRIORITY JOURNAL; PROSTATE CANCER; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; ANIMAL; METABOLISM; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; HUMANS; INTERLEUKIN-6; MALE; MAP KINASE SIGNALING SYSTEM; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 23944441266     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.20477     Document Type: Review

References (74)

1. Adler HI, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC. 1999. Elevated levels of circulating interleukin-6 and transforming growth factor-β1 in patients with metastatic prostatic carcinoma. J Urol 161:182-187.
2. Ayala G, Thompson T, Yang G, Frulov A, Li R, Scardino P, Ohori M, Wheeler T, Harper W. 2004. High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin Cancer Res 10:6572-6578.
3. Bang YJ, Pirnia F, Fang WG, Kang WK, Sartor O, Whitesell L, Ha MJ, Tsokos M, Sheahan MD, Nguyen P, Niklinski WT, Myers CE, Trepel J. 1994. Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP. Proc Natl Acad Sci USA 91:5330-5334.
4. Barton BE, Karras JG, Murphy TF, Barton A, Huang H. 2004. Signal transducer and activator of transcription (STAT3) activation in prostate cancer: Direct STAT3 inhibition induces apoptosis in prostate cancer lines. Mol Cancer Ther 3:11-20.
5. Bellido T, Jilka RL, Boyce BF, Girasole G, Broxmeyer H, Dalrymple SA, Murray R, Manolagas SC. 1995. Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. J Clin Invest 95:2886-2895.
6. Borsellino N, Belldegrun A, Bonavida B. 1995. Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res 55: 4633-4639.
7. Böhm M, Schulte U, Funk JO, Raghunath M, Behrmann I, Kortylewski M, Heinrich PC, Kues T, Luger TA, Schwarz T. 2001. Interleukin-6-resistant melanoma cells exhibit reduced activation of STAT3 and lack of inhibition of cyclin E-associated kinase activity. J Invest Dermatol 117:132-140.
8. Chen CD, Sawyers CL. 2002. NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Mol Cell Biol 22:2862-2870.
9. Chung TD, Yu JJ, Spiotto MT, Bartkowski M, Simons JW. 1999. Characterization of the role of IL-6 in the progression of prostate cancer. Prostate 38:199-207.
10. Chung TD, Yu JJ, Kong TA, Spiotto MT, Lin JM. 2000. Interleukin-6 activates phosphatidylinositol-3 kinase, which inhibits apoptosis in human prostate cancer cell lines. Prostate 42:1-7.
11. Craft N, Shostak Y, Carey M, Sawyers CL. 1999. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5:280-285.
12. Culig Z, Klocker H, Bartsch G, Hobisch A. 2002. Androgen receptors in prostate cancer. Endocr Relat Cancer 9:155-170.
13. Cunnick JM, Meng S, Ren Y, Desponts C, Wang HG, Djeu JY, Wu J. 2002. Regulation of the mitogen-activated protein kinase signaling pathway by SHP2. J Biol Chem 277:9498-9504.
14. Debes JD, Schmidt LJ, Huang H, Tindall DJ. 2002. p300 mediates interleukin-6-dependent transactivation of the androgen receptor. Cancer Res 623:5632-5636.
15. Debes J, Sebo TJ, Lohse CM, Murphy LM, Haugen de AL, Tindall DJ. 2003. p300 in prostate cancer proliferation and progression. Cancer Res 63:7638-7640.
16. Deeble PD, Murphy DJ, Parsons SJ, Cox ME. 2001. Interleukin-6 and cyclic-AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells. Mol Cell Biol 21:8471-8482.
17. Degeorges A, Tatoud R, Fauvel Lafeve F, Podgorniak MP, Millot G, de Cremoux P, Calvo F. 1996. Stromal cells from human benign prostate hyperplasia produce a growth-inhibitory factor for LNCaP prostate cancer cells, identified as interleukin-6. Int J Cancer 68:207-214.
18. Dhanalakshmi S, Singh RP, Agarwal C, Agarwal R. 2002. Silibinin inhibits constitutive and TNFalpha-induced activation of NF-kappaB and sensitizes human prostate carcinoma DU145 to TNFalpha-induced apoptosis. Oncogene 21:1759-1767.
19. Dhir R, Ni Z, Lou W, DeMiguel F, Grandis JR, Gao AC. 2002. Stat3 activation in prostatic carcinomas. Prostate 51:241-246.
20. Fujimoto M, Naka T. 2003. Regulation of cytokine signaling by SOCS family molecules. Trends Immunol 24:659-666.
21. Gao AC, Lou W, Isaacs JT. 2000. Enhanced GBX2 expression stimulates growth of human prostate cancer cells via transcriptional regulation of the interleukin 6 gene. Clin Cancer Res 6:493-497.
22. Giri D, Ozen M, Ittmann M. 2001. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol 159:2159-2165.
23. Godoy-Tundidor S, Hobisch A, Pfeil K, Bartsch G, Culig Z. 2002. Acquisition of agonistic properties of nonsteroidal antiandrogens after treatment with oncostatin M in prostate cancer cells. Clin Cancer Res 8:2356-2361.
24. Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS, Wilson EM. 2001. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 61:4315-4319.
25. Hideshima T, Nakamura N, Chauhan D, Anderson KC. 2001. Biologic sequelae of interleukin-6 induced PI3-K/ Akt signaling in multiple myeloma. Oncogene 20:5991-6000.
26. Hobisch A, Eder IE, Putz T, Horninger W, Bartsch G, Klocker H, Culig Z. 1998. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res 58:4640-4645.
27. Hobisch A, Rogatsch H, Hittmair A, Fuchs D, Bartsch G Jr, Klocker H, Bartsch G, Culig Z. 2000. Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue. J Pathol 191:239-244.
28. Hobisch A, Ramoner R, Fuchs D, Godoy-Tundidor S, Bartsch G, Klocker H, Culig Z. 2001. Prostate cancer cells (LNCaP) generated after long-term interleukin-6 treatment express interleukin-6 and acquire an interleukin-6-partially resistant phenotype. Clin Cancer Res 7:2941-2948.
29. Horiguchi A, Oya M, Marumo K, Murai M. 2002. STAT3, but not ERKs, mediates the IL-6-induced proliferation of renal cancer cells, ACHN and 769P. Kidney Int 61:926-938.
30. Huggins C, Hodges CV. 1941. Studies on prostatic cancer: The effects of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1:293-297.
31. Ismail HA, Lessard L, Mes-Masson AM, Saad F. 2004. Expression of NF-kappa B in prostate cancer lymph node metastases. Prostate 58:308-313.
32. Jia L, Kim J, Shen H, Clark PE, Tilley WD, Coetzee GA. 2003. Androgen receptor activity at the prostate specific antigen locus: Steroidal and non-steroidal mechanisms. Mol Cancer Res 1:385-392.
33. Jia L, Choong CS, Ricciardelli C, Kim J, Tilley WD, Coetzee GA. 2004. Androgen receptor signaling: Mechanism of interleukin-6 inhibition. Cancer Res 64:2619-2626.
34. Keller ET, Chang C, Ershler WB. 1996. Inhibition of NFkappaB activity through maintenance of IkappaBalpha levels contributes to dihydrotestosterone- mediated repression of the interleukin-6 promoter. J Biol Chem 271:26267-26275.
35. Kile BT, Nicola NA, Alexander WS. 2001. Negative regulators of cytokine signaling. Int J Hematol 73:292-298.
36. Kim J, Adam RM, Solomon KR, Freeman MR. 2004. Inolvement of cholesterol-rich lipid rafts in interleukin-6-induced neroendocrine differentiation of LNCaP prostate cancer cells. Endocrinology 145:613-619.
37. Kim O, Jiang T, Xie Y, Guo Z, Chen H, Qiu Y. 2004. Synergism of cytoplasmic kinases in IL6-induced ligand-independent activation of androgen receptor in prostate cancer cells. Oncogene 23:1838-1844.
38. Lee LF, Guan J, Qiu Y, Kung HJ. 2001. Neuropeptide-induced androgen independence in prostate cancer cells: Roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase. Mol Cell Biol 21:8385-8397.
39. Lee SO, Lou W, Hou M, de Miguel F, Gerber L, Gao AC. 2003. Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clin Cancer Res 9:370-376.
40. Lessard L, Mes-Masson AM, Lamarre L, Wall L, Lattouf JB, Saad F. 2003. NF-kappa B nuclear localization and its prognostic significance in prostate cancer. BJU Int 91:417-420.
41. Li Y, Sarkar FH. 2002. Inhibition of nuclear factor kappaB activation in PC-3 cells by genistein is mediated via Akt signaling pathway. Clin Cancer Res 8:2369-2377.
42. Liu XH, Kirschenbaum A, Lu M, Yao S, Klausner A, Preston C, Holland JF, Levine AC. 2002. Prostaglandin E(2) stimulates prostatic intraepithelial neoplasia cell growth through activation of the interleukin-6/GP130/ STAT-3 signaling pathway. Biochem Biophys Res Commun 290:249-255.
43. Matsuda T, Junicho A, Yamamoto T, Kishi H, Korkmaz K, Saatcioglu F, Fuse H, Muraguchi A. 2001. Cross-talk between signal transducer and activator of transcription 3 and androgen receptor signaling in prostate carcinoma cells. Biochem Biophys Res Commun 283: 179-187.
44. Mora LB, Buettner R, Seigne J, Diaz J, Ahmad N, Garcia R, Bowman T, Falcone R, Fairclough R, Cantor A, Muro-Cacho C, Livingston S, Karras XX, Pow-Sang J, Jove R. 2002. Constitutive activation of Stat3 in human prostate tumors and cell lines: Direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res 62:6659-6666.
45. 1 arrest through induction of p27 (Kip1), a cyclin-dependent kinase inhibitor, and neuron-like morphology in LNCaP prostate tumor cells. Biochem Biophys Res Commun 257:609-614.
46. Mori S, Murakami-Mori K, Bonavida B. 1999. Oncostatin M (OM) promotes the growth of DU 145 human prostate cancer cells, but not PC-3 or LNCaP, through the signaling of the OM specific receptor. Anticancer Res 19:1011-1015.
47. Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T, Asakura H, Murai M. 2000. Serum interleuki-6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 6:2702-2706.
48. Nishimura K, Nonomura N, Satoh E, Harada Y, Nakayama M, Tokizane T, Fukui T, Ono Y, Inoue H, Shin M, Tsujimoto Y, Takayama H, Aozasa K, Okuyama A. 2001. Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer. J Natl Cancer Inst 93:1739-1746.
49. Okamoto M, Lee C, Oyasu R. 1997. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res 57:141-146.
50. Park JI, Lee MG, Cho K, Park BJ, Chae KS, Byun DS, Ryu BK, Park YK, Chi SG. 2003. Transforming growth factor-beta1 activates interleukin-6 expression in prostate cancer cell through the synergistic collaboration of the Smad2, p38-NF-kappaB, JNK, and Ras signaling pathways. Oncogene 22:4314-4332.
51. Petrucci MT, Ricciardi MR, Ariola C, Gregori C, Ribersani M, Savino R, Ciliberto G, Tafuri A. 1999. Cell cycle regulation and induction of apoptosis by interleukin-6 variants on the multiple myeloma cell line XG-1. Ann Hematol 78:13-18.
52. Qiu Y, Ravi L, Kung H-J. 1998. Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells. Nature 393:83-85.
53. Royuela M, Ricote M, Parsons MS, Garcia-Tunon I, Paniagua R, de Miguel MP. 2004. Immunohistochemical analysis of the IL-6 family of cytokines and their receptors in benign, hyperplastic, and malignant human prostate. J Pathol 202:41-49.
54. Santhanam U, Ray A, Sehgal PB. 1991. Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proc Natl Acad Sci USA 88:7605-7609.
55. Sarkar FH, Li Y. 2004. Indole-3-carbinol and prostate cancer. J Nutr 134:34938-34988.
56. Shariat SF, Kattan MW, Traxel E, Andrews B, Zhu K, Wheeler TM, Slawin KM. 2004. Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin-6 and its soluble receptor with prostate cancer progression. Clin Cancer Res 10:1992-1999.
57. Shukla S, Gupta S. 2004. Suppression of constitutive and tumor necrosis factor alpha-induced nuclear factor (NF)-kappa B activation and induction of apoptosis by apigenin in human prostate carcinoma PC-3 cells: Correlation with down-regulation of NF-kappaB-responsive genes. Clin Cancer Res 10:3169-3178.
58. Sivashanmugam P, Tang L, Daaka Y. 2004. Interleukin 6 mediates the lysophosphatidic acid-regulated cross-talk between stromal and epithelial prostate cancer cells. J Biol Chem 279:21154-21159.
59. Smith PC, Keller ET. 2001. Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice. Prostate 48:47-53.
60. Spiotto MT, Chung TD. 2000a. STAT3 mediates IL-6-induced growth inhibition in the human prostate cancer cell line LNCaP. Prostate 42:88-98.
61. Spiotto MT, Chung TD. 2000b. STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells. Prostate 42:186-195.
62. Steiner MS, Barrack ER. 1992. Transforming growth factor-beta 1 overproduction in prostate cancer: Effects on growth in vivo and in vitro. Mol Endocrinol 6:15-25.
63. Steiner H, Godoy-Tundidor S, Rogatsch H, Berger AP, Fuchs D, Comuzzi B, Bartsch G, Hobisch A, Culig Z. 2003. Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway. Am J Pathol 162:655-663.
64. Steiner H, Berger AP, Godoy-Tundidor S, Bjartell A, Lilja H, Bartsch G, Hobisch A, Culig Z. 2004. Vascular endothelial growth factor autocrine loop is established in prostate cancer cells generated after prolonged treatment with interleukin-6. Eur J Cancer 40:1066-1072.
65. Stratton MS, Sirvent H, Udayakumar TS, Nagle RB, Bowden GT. 2001. Expression of the matrix metalloproteinase promatrilysin in coculture of prostate carcinoma cell lines. Prostate 48:206-209.
66. Twillie DA, Eisenberger MA, Carducci MA, Hseih W-S, Kim WY, Simons JW. 1995. Interleukin-6: A candidate mediator of human prostate cancer morbidity. Urology 45:542-549.
67. Ueda T, Bruchovsky N, Sadar MD. 2002a. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem 277:7076-7085.
68. Ueda T, Mawji NR, Bruchovsky N, Sadar MD. 2002b. Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J Biol Chem 277:38087-38094.
69. Uzgare AR, Isaacs JT. 2004. Enhanced redundancy in Akt and mitogen-activated protein kinase-induced survival of malignant versus normal prostate epithelial cells. Cancer Res 64:6190-6199.
70. Wang LH, Yang XY, Zhang X, Huang J, Hou J, Li J, Xiong H, Mihalic K, Zhu H, Xiao W, Farrar WL. 2004. Transcriptional inactivation of STAT3 by PPARgamma suppresses IL-6-responsive multiple myeloma cells. Immunity 20:205-218.
71. Wang Q, Horiatis D, Pinski J. 2004. Interleukin-6 inhibits the growth of prostate cancer xneografts in mice by the process of neuroendocrine differentiation. Int J Cancer 111:508-513.
72. Zaki MH, Nemeth JA, Trikha M. 2004. CNTO328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice. Int J Cancer 111:592-595.
73. Zelivianski S, Verni M, Moore C, Kondrikov D, Taylor R, Lin MF. 2001. Multipathways for transdifferentiation of human prostate cancer cells into neuroendocrine-like phenotype. Biochim Biophys Acta 1539:28-43.
74. Zerbini LF, Wang Y, Cho JY, Libermann TA. 2003. Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer. Cancer Res 63: 2206-2215.